PMVP
PMV Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.29
+4.03%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+15.6%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 5, 2026 | LEVINE ARNOLD J · director | A-Award | 42,000 | $1.19 |
| Jun 5, 2026 | Gallagher Carol Giltner · director | A-Award | 42,000 | $1.19 |
| Jun 5, 2026 | FLOWERS KIRSTEN · director | A-Award | 42,000 | $1.19 |
| Jun 5, 2026 | BAUM CHARLES M · director | A-Award | 42,000 | $1.19 |
| Jun 5, 2026 | Stelzer Laurie · director | A-Award | 42,000 | $1.19 |
| Mar 9, 2026 | Jalota Deepika · officer: Chief Development Officer | A-Award | 303,310 | $1.53 |
| Mar 9, 2026 | Ticktin Robert · officer: General Counsel & COO | A-Award | 319,270 | $1.53 |
| Mar 9, 2026 | Carulli Michael · officer: Chief Financial Officer | A-Award | 240,000 | $1.53 |
| Mar 9, 2026 | Mack David Henry · director, officer: President and CEO | A-Award | 744,960 | $1.53 |
| Oct 29, 2025 | Mack David Henry · director, officer: President and CEO | M-Exempt | 220,643 | $1.37 |
| Oct 27, 2025 | ORBIMED ADVISORS LLC · 10 percent owner | Sale | 1,000,000 | $1.52 |
| Sep 12, 2025 | ORBIMED ADVISORS LLC · 10 percent owner | Sale | 500,000 | $1.80 |
| Jul 3, 2025 | Mack David Henry · director, officer: President and CEO | Sale | 58,411 | $1.06 |
| Jul 3, 2025 | Ticktin Robert · officer: General Counsel & COO | Sale | 23,151 | $1.06 |
| Jul 3, 2025 | Jalota Deepika · officer: Chief Development Officer | Sale | 33,065 | $1.06 |
| Jul 3, 2025 | Carulli Michael · officer: Chief Financial Officer | Sale | 28,249 | $1.06 |
| Jun 9, 2025 | FLOWERS KIRSTEN · director | A-Award | 33,500 | $0.95 |
| Jun 9, 2025 | BAUM CHARLES M · director | A-Award | 33,500 | $0.95 |
| Jun 9, 2025 | Stelzer Laurie · director | A-Award | 33,500 | $0.95 |
| Jun 9, 2025 | LEVINE ARNOLD J · director | A-Award | 33,500 | $0.95 |
| Jun 9, 2025 | Heyman Richard A. · director | A-Award | 33,500 | $0.95 |
| Jun 9, 2025 | Gallagher Carol Giltner · director | A-Award | 33,500 | $0.95 |
| Mar 5, 2025 | Carulli Michael · officer: Chief Financial Officer | A-Award | 265,000 | $1.32 |
| Mar 5, 2025 | Mack David Henry · director, officer: President and CEO | A-Award | 800,000 | $1.32 |
| Mar 5, 2025 | Jalota Deepika · officer: Chief Development Officer | A-Award | 300,000 | $1.32 |
| Jan 22, 2025 | Mack David Henry · director, officer: President and CEO | M-Exempt | 17,709 | $0.53 |
| Jan 22, 2025 | Mack David Henry · director, officer: President and CEO | M-Exempt | 91,750 | $0.53 |
| Oct 3, 2024 | Carulli Michael · officer: Chief Financial Officer | A-Award | 40,805 | $1.48 |
| Oct 3, 2024 | Mack David Henry · director, officer: President and CEO | A-Award | 384,184 | $1.48 |
| Oct 3, 2024 | Mack David Henry · director, officer: President and CEO | A-Award | 330,000 | $1.48 |
Institutional positioning
13F filings over the trailing two quarters
New 15Increased 17Reduced 22Sold out 68
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | Increased | 5,320,000 | May 6, 2026 |
| TANG CAPITAL MANAGEMENT LLC | Reduced | 4,245,085 | May 15, 2026 |
| SIO CAPITAL MANAGEMENT, LLC | Increased | 3,076,580 | May 14, 2026 |
| ARROWMARK COLORADO HOLDINGS LLC | Reduced | 2,872,764 | May 15, 2026 |
| EUCLIDEAN CAPITAL LLC | Unchanged | 2,627,643 | May 15, 2026 |
| EVERSEPT PARTNERS, LP | New Position | 2,348,360 | May 15, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | Increased | 2,215,894 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,974,906 | May 15, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 1,884,530 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | New Position | 1,860,000 | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 874,374 | May 13, 2026 |
| MORGAN STANLEY | Increased | 864,311 | May 15, 2026 |
| STONEPINE CAPITAL MANAGEMENT, LLC | Reduced | 708,102 | May 14, 2026 |
| LONGAEVA PARTNERS L.P. | New Position | 552,027 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 495,922 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 5, 2026